Cover Image
Read Now

Clinical review report: Letermovir (Prevymis) (Merck Canada Inc.)

According to the Health Canada-approved indication, letermovir can be used for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Therefore, the objective of this review is to perform a systematic review...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, July 2018
Series:CADTH common drug review
Subjects:
Canada
Cytomegalovirus Infections / Drug Therapy
Acetates / Therapeutic Use
Antiviral Agents / Therapeutic Use
Quinazolines / Therapeutic Use
Hematopoietic Stem Cell Transplantation
Antibiotic Prophylaxis / Methods
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:According to the Health Canada-approved indication, letermovir can be used for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Therefore, the objective of this review is to perform a systematic review of the beneficial and harmful effects of letermovir for the prophylaxis of CMV infection in adult CMV-seropositive recipients of an allogeneic HSCT.
Item Description:"Version: Final."
Physical Description:1 PDF file (93 pages) illustrations

Similar Items